Role of Heparin in Poor Responders Undergoing In Vitro Fertilisation

This study is currently recruiting participants.
Verified November 2013 by National and Kapodistrian University of Athens
Sponsor:
Information provided by (Responsible Party):
Siristatidis Charalampos, MD, PhD, National and Kapodistrian University of Athens
ClinicalTrials.gov Identifier:
NCT01315093
First received: March 8, 2011
Last updated: November 29, 2013
Last verified: November 2013

March 8, 2011
November 29, 2013
November 2010
December 2014   (final data collection date for primary outcome measure)
ongoing pregnancy rate [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
The presence of fetal heart on ultrasound after 12 weeks of gestation
Οngoing pregnancy rate [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
The presence of fetal heart on ultrasound after 12 weeks of gestation
Complete list of historical versions of study NCT01315093 on ClinicalTrials.gov Archive Site
Evidence and rate of clinical pregnancy [ Time Frame: 6+2 gestational weeks ] [ Designated as safety issue: No ]
Presence of fetal heart at transvaginal ultrasound at 6+2 gestational weeks
Same as current
Not Provided
Not Provided
 
Role of Heparin in Poor Responders Undergoing In Vitro Fertilisation
Not Provided

The addition of heparin increases pregnancy outcome parameters in poor responders undergoing In Vitro Fertilisation (IVF)

Not Provided
Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Infertility
Drug: Heparin, Low-Molecular-Weight
Experimental: Heparin
LMWH was administered during an IVF cycle using either the agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation
Intervention: Drug: Heparin, Low-Molecular-Weight
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
December 2014
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • poor responders
  • infertility
  • no contraindications for heparin
Female
25 Years to 43 Years
Yes
Contact: Charalampos S Siristatidis, Ass Professor 6932294994 ext 0030 harrysiri@yahoo.gr
Greece
 
NCT01315093
123456
Not Provided
Siristatidis Charalampos, MD, PhD, National and Kapodistrian University of Athens
National and Kapodistrian University of Athens
Not Provided
Not Provided
National and Kapodistrian University of Athens
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP